The Impact of CD34 < sup > + < /sup > Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma

CONCLUSION: Although bortezomib is not considered stem-cell toxic, it may be associated with lower stem cell collection yields. Bortezomib's efficacy at induction may partially explain the improved outcomes, however, other factors may be involved, and are discussed. We can conclude that with our large cohort and long follow-up, high stem-cell mobilization does not appear to predict for a long-term survival advantage.PMID:37689547 | DOI:10.1016/j.clml.2023.07.014
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research